Arango, Celso
Fagiolini, Andrea
Gorwood, Philip
Kane, John M.
Diaz-Mendoza, Sergio
Sahota, Navdeep
Correll, Christoph U.
Funding for this research was provided by:
H. Lundbeck A/S (NA, NA, NA, NA, NA, NA, NA)
Article History
Received: 16 February 2023
Accepted: 6 June 2023
First Online: 21 June 2023
Declarations
:
: While the authors do not have any competing interests as defined by BMC, the following are the author disclosures: Celso Arango has received support by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda.Philip Gorwood received during the last 5 years fees for presentations at congresses or participation in scientific boards from Angelini, EISI, Janssen, Lundbeck, Otsuka, Richter, Merk and Viatris.John M. Kane has been a consultant for or received honoraria from Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Newron, Novartis, Otsuka, Roche, Saladax, Sunovion, and Teva. Dr. Kane has received grant support from Otsuka, Lundbeck, Sunovion and Janssen. Dr. Kane is a Shareholder in Vanguard Research Group, North Shore Therapeutics, Health Rhythms, MedinCell, and LB Pharmaceuticals, Inc.Andrea Fagiolini is /has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Daiichi Sankyo, Glaxo Smith Kline, Italfarmaco, Lundbeck, Janssen, Mylan, Otsuka, Pfizer, Recordati, Sanofi Aventis, Sunovion, Viatris, ViforChristoph U Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic.
: was sought from Pearl Pathways (reference: #23-OHTH-106, 30/1/2023), a central Institutional Review Board who reviewed and approved all study material including the protocol. Given the fact that no individual patient data was collected in the course of this study and physician participation was voluntary, this study was determined to be <b>Exempt</b> according to the FDA 21 CFR 56.104 and 45CFR46.104(d)(2). The study was conducted in accordance with the relevant guidelines and regulations for research involving human subjects. Information on study purpose, format and outputs were provided to the panelists through a market research agreement document. Informed consent was obtained from all panelists before their participation in this Delphi panel.
: N/A.